Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical and Vaccine Immunology

• Publication date

  2014-01-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/CVI.00748-13PMID 24403525PMCID PMC3957658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants

  2012cited by this paper
• Lower-Sensitivity and Avidity Modifications of the Vitros Anti-HIV 1+2 Assay for Detection of Recent HIV Infections and Incidence Estimation

  2012cited by this paper
• Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

  2012cited by this paper
• Vaccine-induced HIV seropositivity: a problem on the rise.

  2011cited by this paper
• Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

  2011cited by this paper
• A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

  2011cited by this paper
• Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys

  2011cited by this paper
• HIV Screening via Fourth-Generation Immunoassay or Nucleic Acid Amplification Test in the United States: A Cost-Effectiveness Analysis

  2011cited by this paper
• The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA

  2011cited by this paper
• Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

  2011cited by this paper
• Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.

  2010influential reference
• AIDS vaccine 2010.

  2010cited by this paper
• Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting

  2010cited by this paper
• Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

  2009cited by this paper
• Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity

  2008cited by this paper
• Towards prediction of degenerate CTL epitope recognition

  2008cited by this paper
• Long-Term Persistence of Vaccine-Induced HIV Seropositivity among Healthy Volunteers

  2008cited by this paper
• HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.

  2008cited by this paper
• Increased Sequence Diversity Coverage Improves Detection of HIV-Specific T Cell Responses1

  2007cited by this paper
• Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial

  2007influential reference
• Enhanced Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Nef-Specific T Cells Recognizing Multiple Variants in Early HIV-1 Infection

  2007cited by this paper
• Negative Social Impacts Among Volunteers in an HIV Vaccine Efficacy Trial

  2007cited by this paper
• Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

  2006cited by this paper
• Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies

  2006cited by this paper
• Novel Approach for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies: Utility for Detection of Diverse HIV-1 Subtypes

  2006cited by this paper
• Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

  2005cited by this paper
• High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.

  2005influential reference
• Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.

  2003cited by this paper
• Impact of HIV vaccination on laboratory diagnosis: case reports

  2002cited by this paper
• Trial-Related Discrimination in HIV Vaccine Clinical Trials

  2001cited by this paper
• Interpreting HIV Serodiagnostic Test Results in the 1990s: Social Risks of HIV Vaccine Studies in Uninfected Volunteers

  1994cited by this paper

• Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand.

  2025cites this paper
• Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants

  2025cites this paper
• HIV Diagnostics and Vaccines: It Takes Two to Tango.

  2024cites this paper
• Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants

  2023cites this paper
• Towards Novel HIV-1 Serodiagnostic Tests without Vaccine-Induced Seroreactivity

  2023cites this paper
• Vaccine-Induced Seroreactivity Impacts the Accuracy of HIV Testing Algorithms in Sub-Saharan Africa: An Exploratory Study

  2022cites this paper
• Enzyme-assisted metal nanoparticles etching based plasmonic ELISA: Progress and insights.

  2022cites this paper
• Exploring a community's understanding of HIV vaccine‑induced seropositivity in a South African research setting.

  2022cites this paper
• Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees

  2020cites this paper
• Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges

  2020cites this paper
• Progress of gold nanomaterials for colorimetric sensing based on different strategies

  2020cites this paper
• Human immunodeficiency virus: Diagnostic approach.

  2017cites this paper
• The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update

  2016cites this paper
• Dual-color plasmonic enzyme-linked immunosorbent assay based on enzyme-mediated etching of Au nanoparticles

  2016cites this paper
• eview IV vaccine-induced sero-reactivity : A challenge for trial participants , esearchers , and physicians ISR Working Group of the Global HIV Vaccine Enterprise

  2015cites this paper
• Testing for HIV – the first three decades

  2015cites this paper
• HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.

  2015cites this paper